Trulieve Cannabis (TRLV) Stock
Trulieve Cannabis's price implies about -5% free cash flow growth a year.
Key numbers
- P/E (forward)
- 21.8x
- Revenue growth
- -9.1%
- Operating margin
- -25.6%
- Debt / equity
- 0.25x
What Trulieve Cannabis's price implies
From a reverse DCF on Trulieve Cannabis's SEC filings.
- Free cash flow, last 2 years
- 18.6%a year
- Revenue, same period
- 29.3%a year
At a market value of $2.0B, Trulieve Cannabis's free cash flow of $212M (fiscal 2025) would need to grow about -5% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 2 years. A 9% discount rate and 3% growth after year 10 (how it works). Change them in the Modeling tab or the reverse DCF calculator.
Revenue and free cash flow
Fiscal years, from Trulieve Cannabis's 10-K filings.
Trulieve Cannabis revenue and free cash flow
FY2019–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $932M | $1.2B | $1.1B | $1.2B | $1.2B |
| Net income | $17M | -$246M | -$527M | -$155M | -$116M |
| Free cash flow | -$267M | -$151M | $151M | $124M | $212M |
| EPS (diluted) | $0.21 | -$0.95 | -$2.28 | -$0.79 | -$0.58 |
| Operating margin | 21.9% | 4.1% | -19.6% | 8.2% | 12.1% |
Where the revenue comes from
By products, fiscal 2025. By year
Superinvestors who own TRLV
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held TRLV in their latest 13F.
Trulieve Cannabis insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of TRLV in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from TRLV's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Trulieve Cannabis compares
Trulieve Cannabis's P/FCF is higher than 14% of Healthcare companies and 26% of the 2,359 companies with a P/FCF figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| P/FCF | 14% | 26% |
| Revenue growth | 18% | 9% |
| Operating margin | 35% | 14% |
| ROE | 23% | 8% |
Questions about Trulieve Cannabis
What growth does Trulieve Cannabis's stock price imply?
At a market value of $2.0B, Trulieve Cannabis would need its free cash flow to grow about -5% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 2 years its free cash flow grew 19% a year.
Are Trulieve Cannabis insiders buying the stock?
No open-market insider purchases of TRLV in the last 12 months, according to SEC Form 4 filings.
Companies like Trulieve Cannabis
BioCryst Pharmaceuticals Inc (BCRX)$2.0BPrestige Brand Holdings Inc (PBH)$2.0BPerrigo Company PLC (PRGO)$2.2BEton Pharmaceuticals Inc (ETON)$1.6BHUTCHMED DRC (HCM)$2.5BANI Pharmaceuticals Inc (ANIP)$1.5BSupernus Pharmaceuticals, Inc. (SUPN)$1.5BAlvotech (ALVO)$1.5BRegencell Bioscience Holdings Ltd (RGC)$2.6B All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.